

REMARKS

Claims 34-38 have been canceled without prejudice or disclaimer as being drawn to a non-elected invention. The applicant reserves the right to pursue these claims in one or more divisional applications.

Claims 10, 25, and 32 have been amended to address the objections lodged in the office action. In particular, claim 10 has been amended to correct the grammar and to include a missing word as identified in the office action; claim 25 has been amended to include italics, and claim 32 has been amended to correct for spelling errors.

Claim 32 was amended to eliminate the recitation of multiple time periods in order to overcome the rejection under 35 U.S.C. 112, second paragraph. Claim 29 was canceled for the purpose of accelerated prosecution and making moot the rejection lodged under 35 U.S.C. 112, second paragraph. The applicant reserves the right to pursue a claim (or claims) directed to the subject matter of claim 29 in one or more continuing applications.

To accelerate prosecution, claim 10 was amended to incorporate features of claims 28 and 33. Claim 27 has been amended to address claim dependency. The application now includes claims 10, 25-27, and 30-32.

Paragraph [0026] of the published application (4th paragraph on page 6 of the application) indicates that the preferred IFN γ receptor agonist is human interferon gamma or a variant thereof, and defines the variants as those having sufficient activity to bind to the IFN γ receptor. Claim 10 has been amended to limit the IFN γ receptor agonist in the manner defined in the application (this amendment addresses the rejection of claims 10 and 25-33 under 35 U.S.C. 112, first paragraph). Further, the *in vitro* and *in vivo* Examples (Examples 1 and 2 beginning on page 12 of the application) use IFN γ . Furthermore, the experimental results (both *in vitro* and *in vivo*) are focused on effects related to allergic reactions (e.g., the experiments utilize a dust mite allergen, DerP1, from *Dermatophagoides pteronyssinus*). Thus, to accelerate prosecution, claim 10 has been amended to be focused on a composition used for the treatment of allergic disorders (this amendment addresses the rejection of claim 33 (identified in error as claim 32) under 35 U.S.C. 112, first paragraph). Finally, to further highlight

the invention, claim 10 has been amended to require that the bisacyloxypropyl-S-cystein derivative has the biological activity of macrophage activating lipopeptide 2 (MALP-2). Paragraphs [0027] and [0028] of the published application (last paragraph on page 6 and first paragraph on page 7 of the application) support this amendment. As explained in paragraph [0086] of the published application (the paragraph bridging pages 24 and 25) the TLR-2/6 agonist MALP-2 is used in combination with IFN γ to shift a Th2 skewed immunoresponse to a Th1 immunoresponse (e.g., as explained in Example 1 (Paragraph [0069] of the published application), by stimulating DC with MALP-2 and IFN γ , IL4 production was held fairly much in check (less than doubled) while there was a fifty fold increase in IFN γ production; and the *in vivo* results in Example 2 showed the combination of MALP-2 and IFN γ reduced Th2 cytokines and induced IL-12p70 (paragraph [0079] of the published application).

The experiments set forth in Examples 1 and 2 show that DC pretreated with MALP 2 together with IFN γ upregulate lymphocyte proliferation and induce Th1 responses. As is demonstrated by numerous publications referred to in the prior art section (see paragraph [0007] of the published application), prior efforts involving stimulation of DC through toll like receptors did not suffice to induce a Th1 response. Only the applicant has shown a mechanism to obtain a Th1 type immune response (this response having particular utility allergic disorders and in other applications). Examples 1 and 2 of the application demonstrate that use of MALP 2 or IFN γ alone with DC does not yield this result, i.e., there is a synergy in the combination that is achieved that heretofore had not been identified. As set forth in the claimed invention, the therapeutic compositions for treating allergic disorders contain dendritic cells (DC) and/or lymphocytes cocultivated with said DC, wherein said DC have acquired the property to drive a T helper cell type I response, obtainable by a method comprising the step of culturing DC in the presence of

- (1) interferon (IFN) gamma or a variant thereof capable of binding to an IFN gamma receptor, and
- (2) a TLR 2 and TLR 6 agonist that is a bisacyloxypropyl-S-cystein derivative having the biological activity of macrophage activating lipopeptide 2 (MALP-2).

All claims were rejected as being anticipated by WO 03/022215 to Bosch as evidenced by the Farhat and Heldewein references. In addition, all claims were rejected as being obvious over Re. These rejections are traversed.


Bosch describes cultivation of immature DC in the presence of BCG and IFN γ . Purportedly, Bosch indicates that co-cultivation of immature DC results in dendritic cells that are allowed to polarize T cells toward T helper type 1. It is not known whether this occurs; however, this is a different matter from the claimed invention. BCG is a crude extract of whole bacteria and not a defined compound as claimed in claim 10 of the present case. That is, BCG is not identical to (or even similar to) bisacyoxypropyl-S-cysteine derivative having the biological activity of MALP-2. Moreover, the Heldwin reference demonstrates BCG acts via TLR2 and TLR4. In contrast, the bisacyoxypropyl-S-cysteine derivative does not act via TLR4. Further, Heldwin identifies on page 277, right column, that there are differences between LPS derived from different sources and can either act as a TLR2 or a TLR4 agonist. Finally, Bosch is silent about treatment of allergic disorders.

As Bosch is not drawn to a composition for treating allergic disorders, and does not show or suggest the use of pretreated dendritic cells using the claimed combination of agents used in cocultivation, and because the Examples 1 and 2 of the present application demonstrate that the combination matters, none of the claims are anticipated by Bosch (and would not be obvious over Bosch in view of any reference of record).

Re describes the ability of a peptidoglycan (PGN) to act as a TLR4 agonist and TLR2 agonist. In this connection, the observation described by Re et al. Was reverted to Travassos, EMBO Rep. 2004, 5 (10) 1000-1006 (copy attached to this amendment) which identifies PGN used by Re was contaminated with LPS, thus resulting in acting via TLR2 and TLR4. Re is also not drawn to a composition for treating allergic disorders and does not show or suggest the use of pretreated dendritic cells using the claimed combination of agents used in cocultivation. Hence, Re does not make obvious the claimed subject matter.

In view of the above, reconsideration and allowance of claims 10, 25-27,
and 30-32 at an early date is requested.

Respectfully submitted,



Michael E. Whitham
Reg. No. 32,635

Whitham, Curtis, Christofferson & Cook, P.C.
11491 Sunset Hills Road, Suite 340
Reston, VA 20190

Tel. (703) 787-9400
Fax. (703) 787-7557

Customer No.: 30743

Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition

Leonardo H. Travassos^{1,5}, Stephen E. Girardin², Dana J. Philpott¹, Didier Blanot⁶, Marie-Anne Nahori³, Catherine Werts³ & Ivo G. Boneca⁴⁺

¹Groupe d'Immunité Innée et Signification, ²Unité de Pathogénie Microbienne Moléculaire, ³Unité Postulante Cytokines et Inflammation, and ⁴Unité de Pathogénie Bactérienne des Muqueuses, Institut Pasteur, Paris, France, ⁵Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil, and ⁶Envirobilles Bactériennes et Antibiotiques, Institut de Biochimie et Biophysique Moléculaire et Cellulaire, Université Paris-Sud, Orsay, France

Toll-like receptor 2 (TLR2) has been shown to recognize several classes of pathogen-associated molecular patterns including peptidoglycan (PG). However, studies linking PG with TLR2 recognition have relied mainly on the use of commercial *Staphylococcus aureus* PG and have not addressed TLR2 recognition of other PG types. Using highly purified PGs from eight bacteria (*Escherichia coli*, *Pseudomonas aeruginosa*, *Versinia pseudotuberculosis*, *Helicobacter pylori*, *Bacillus subtilis*, *Listeria monocytogenes*, *Streptococcus pneumoniae* and *S. aureus*), we show that these PGs are not sensed through TLR2, TLR2/1 or TLR2/6. PG sensing is lost after removal of lipoproteins or lipoteichoic acids (LTAs) from Gram-negative and Gram-positive cell walls, respectively. Accordingly, purified LTAs are sensed synergistically through TLR2/1. Finally, we show that elicited peritoneal murine macrophages do not produce tumour necrosis factor- α or interleukin-6 in response to purified PGs, suggesting that PG detection is more likely to occur intracellularly (through Nod1/Nod2) rather than from the extracellular compartment.

Keywords: peptidoglycan; LTA; Nod2; cytokine; macrophage; TLR

EMBO reports (2004) 5, 1900–1906. doi:10.1038/sj.emboj.7480248

INTRODUCTION

The discovery of Toll-like receptors (TLRs) markedly increased our understanding of how the innate immune system recognizes and triggers a response towards microbes (Takeda & Akira, 2003). TLRs detect pathogen-associated molecular patterns (PAMPs) and mediate the induction of pro-inflammatory cytokines and co-stimulatory cell-surface molecules through the activation of transcription factors such as nuclear factor- κ B (NF- κ B). These responses then contribute to the clearance of the infectious agent from the host organism.

The best-characterized TLRs are TLR4 and TLR2. Whereas TLR4 recognizes lipopolysaccharide (LPS), TLR2 recognizes several molecules including lipoteichoic acid (LTA), lipooligosaccharide, lipoproteins and peptidoglycan (PG), which is a polymer composed of repeating *N*-acetylglucosamine- β -1,4-*N*-acetylmuramic acid (GlcNAc-MurNAc) disaccharide units linked by short peptides. Although the role of TLR2 as a PG receptor has been extensively examined, these studies have been mainly conducted with commercial *Staphylococcus aureus* PG preparations (Takeda & Akira, 2003). During our investigations describing the muramyltripeptide recognized by the cytosolic PG sensor Nod1 (Girardin *et al.*, 2003a), we observed that highly purified PGs did not elicit TLR2-dependent activation in transiently transfected HEK293T cells. Consequently, we hypothesized that TLR2-PG stimulatory activity could be attributed to other cell wall components present in commercial PG preparations or partially purified PG.

Here, we used highly purified PGs from eight different Gram-positive and Gram-negative bacteria to clearly show that purified PG is not detected by TLR2. The observed PG stimulatory activity towards TLR2 is due to the presence of LTA or lipoproteins in the cell walls from Gram-positive or Gram-negative bacteria, respectively.

RESULTS AND DISCUSSION

Does TLR2 recognize different PGs?

Different PG chemotypes differ mainly according to variations in the third amino acid of the peptidic chain and the nature of the

¹Groupe d'Immunité Innée et Signification, ²Unité de Pathogénie Microbienne Moléculaire, ³Unité Postulante Cytokines et Inflammation, ⁴Unité de Pathogénie Bactérienne des Muqueuses, Institut Pasteur, 28 Rue du Dr Roux, 75724 Paris cedex 15, France

⁵Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde, Bloco 1-Cidade Universitária-Uma do Fundão, CEP 21941-390 Rio de Janeiro-RJ, Brasil

⁶Envirobilles Bactériennes et Antibiotiques, Institut de Biochimie et Biophysique Moléculaire et Cellulaire, Unité Mixte de Recherche 8619 CNRS, Université Paris-Sud, 91405 Orsay, France

⁺Corresponding author. Tel: +33 1 4438 9516; Fax: +33 1 4061 3640; E-mail: boneca@pasteur.fr

Received 19 May 2004; revised 3 August 2004; accepted 16 August 2004; published online 10 September 2004

crossbridge. We prepared highly purified PGs from Gram-positive and Gram-negative bacteria and tested their recognition by TLR2 at different steps of the purification procedure. Due to their distinct cell wall architecture, the purification procedure outlined in supplementary Fig 1 online, is radically different between Gram-negative and Gram-positive bacteria.

As Nod2 detects muramyl dipeptide (MDP; Girardin et al., 2003b; Inohara et al., 2003), and thus can detect PG purified from either Gram-negative or Gram-positive bacteria, we co-transfected Nod2 in HEK293T cells with the same amount of partially or highly purified PG as a positive control for our purification procedures. Accordingly, with increasing purity of PG, we observed higher levels of Nod2-dependent NF- κ B activation (Fig. 1A,C). However, all PG preparations from *S. aureus* and *Streptococcus pneumoniae* elicited a poor activation through Nod2. Muramidase digestion of *S. aureus* PG did not enhance Nod2-dependent activity due to the fact that it produces trace amounts of MDP (de Jonge et al., 1992). In contrast, muramidase digestion of *S. pneumoniae* PG produced a tenfold increase in Nod2-dependent NF- κ B activation (H.L. Travassos and J.G. Boneca, unpublished observations) consistent with higher amounts of MDP. Finally, analyses of the amino-sugar and amino-acid composition for the eight highly purified PGs (Table 1) were consistent with previous reports indicating that at the end of the purification procedure, no other contaminants were present

(Schleifer & Kandler, 1972; Quintela et al., 1995; Costa et al., 1999). The presence of LTA/wall teichoic acid (WTA) in these highly purified Gram-positive PG preparations would have given higher glucosamine/muramic acid (>2) and D-alanine/diamino acid (>3) ratios for *S. aureus*, *Listeria monocytogenes* and *Bacillus subtilis*, whereas for *S. pneumoniae* we would have also detected galactosamine.

Samples of each PG purification step were then tested for their ability to induce TLR2-dependent activity in transiently transfected HEK293T cells (Fig. 1B,C). A general feature was that whereas TLR2 could detect some crude PG preparations from the initial purification steps, TLR2-dependent sensing was systematically lost after the last step of PG purification. Cell wall preparations from *Helicobacter pylori* and *S. aureus* lost their TLR2-activating ability immediately at the first purification step. Loss of TLR2-dependent activity was observed despite the fact that approximately 1 μ g of PG was added to the cells (equal to 10^7 - 10^8 colony-forming units (CFUs); see Table 1). Note that we consider using higher amounts as physiologically artificial.

Interestingly, *Escherichia coli* and *Pseudomonas aeruginosa* cell walls lost their TLR2 stimulatory activity only after trypsin treatment (step 2a), arguing that Braun lipoprotein or analogous lipoproteins covalently anchored to these two PGs were responsible for TLR2 activation (Glauner, 1988; Quintela et al., 1995). Accordingly, *H. pylori* and *Yersinia pseudotuberculosis* PGs,




Fig. 1 | Gram-negative (A,B) and Gram-positive (C,D) PG was purified and samples from each purification step were used to stimulate Nod2- (A,C) or TLR2- (B,D) transfected HEK293T cells. The purified PG preparations numbered 1-3 correspond to the different purification steps (supplementary Fig 1 online).

Table 1 | Amino-sugar and amino-acid composition of the different PGs

PGN	GlcNAc	MurNAc	Ala	Glx	Diamino acid*	Gly	Ser	Others	CFU equivalent to 1 µg PGN
<i>E. coli</i>	1.03	0.88	2.04	1.17	1	0.17	0.10	0.08	3.3–5 × 10 ⁸
<i>P. aeruginosa</i>	0.98	0.94	1.88	1.25	1	0.17	0.13	0.08	~5 × 10 ⁸
<i>Y. pseudotuberculosis</i>	0.96	0.92	2.08	1.22	1	0.13	0.07	0.05	~5 × 10 ⁸
<i>H. pylori</i>	0.99	0.91	2.00	1.21	1	1.16	0.10	0.05	1.6–3.2 × 10 ⁸
<i>B. subtilis</i>	0.97	0.86	1.71	1.22	1	0.13	0.09	0.07	~5 × 10 ⁷
<i>L. monocytogenes</i>	0.93	0.76	1.67	1.20	1	0.05	0.04	0.02	3.3–6.25 × 10 ⁷
<i>S. aureus</i>	0.89	0.67	2.23	1.55	1	4.13	0.49	0.21	1.25–6.6 × 10 ⁷
<i>S. pneumoniae</i>	0.85	0.62	2.22	1.27	1	0.21	0.36	0.16	~5 × 10 ⁷

*The diamino acid corresponds to L-lysine for *S. aureus* and *S. pneumoniae*, and meso-diaminopimelic acid for the remaining species. Values correspond to molar ratios taking diamino acid as the reference.

which do not have an equivalent covalently PG-bound lipoprotein (Costa et al., 1999; I.G. Boneca, unpublished observations), showed no TLR2-stimulating activity even at the first purification step.

Does TLR2 sense commercial and soluble PG?

The results presented above suggested that the activation of TLR2 by commercial *S. aureus* PG preparations was due to the presence of contaminating molecules. Hence, we compared the ability of 'raw' and partially re-purified commercial *S. aureus* PG to stimulate cells via TLR2. Interestingly, when commercial *S. aureus* PG was submitted to our first purification step (supplementary Fig 1 online), which removes most LTA and noncovalently bound lipoproteins, the TLR2-dependent stimulatory activity was lost (Fig 2A).

Soluble PG (sPG), as prepared by Schwandner et al. (1999), is released by growing staphylococci at subinhibitory concentrations of penicillin, and sPG purified by vancomycin-affinity chromatography is reported to be a potent TLR2 agonist. Thus, we extended our studies to examine the effect of sPG on TLR2-dependent NF-κB activation. As we used an alternative approach to purify PG, we rendered *S. aureus* PG soluble by cleaving the pentaglycine bridges with lysostaphin, mimicking the effect of penicillin on sPG. However, lysostaphin treatment did not result in a TLR2 recognition of sPG (Fig 2B). To ascertain that the lysostaphin treatment was effective, we verified that sPG was able to activate Nod2 (Fig 2C). Furthermore, high-performance liquid chromatography (HPLC) analysis of the sPG showed a profile consistent with previous reports (Fig 2D; Sieradzki et al., 1999).

However, this contradiction can be explained by the fact that the procedure used by Schwandner and colleagues does not remove WTAs, which remain attached to PG. Furthermore, penicillin also induces a massive release of LTA (Tomasz & Waks, 1975; van Langevelde et al., 1996). Therefore, the sPG isolated using this protocol is potentially enriched in LTA. In fact, some studies use a tenfold higher concentration of sPG, therefore increasing the amount of 'contaminants'.

TLR2 confers responsiveness to heat-killed bacteria

As some crude PGs/cell walls did not induce TLR2, we wanted to ascertain that heat-killed (HK) bacteria *per se* were able to induce

TLR2-dependent activation. To investigate this, we used HK bacterial suspensions standardized to obtain the same PG amount by gross (approximately 0.5–1 µg; see Table 1). Even though the bacterial suspensions presented similar PG amounts, TLR2 expression did not confer responsiveness to HK *S. aureus* and *S. pneumoniae* (Fig 3A).

As *S. aureus* and *S. pneumoniae* are able to induce strong TLR2-dependent NF-κB activation, we repeated these experiments with increasing amounts of HK bacteria. Interestingly, TLR2-dependent NF-κB activation was dose-dependent and maximal only when all HK bacteria were present at roughly the same CFU per millilitre (Fig 3B). These results clearly indicate that TLR2 activation is bacterial concentration dependent, rather than PG content dependent, thereby arguing that additional cell wall components mediate TLR2-dependent activation.

TLR1 and TLR6 do not confer TLR2 responsiveness to PG

Recognition of triacyl and diacyl lipopeptides may require the formation of TLR2/1 and TLR2/6 heterodimers, respectively (Takeda & Akira, 2003). We decided to test whether TLR1 or TLR6 enhance PG sensing. The co-transfection of TLR1 and TLR6 with TLR2 did not result in PG-stimulated NF-κB activation (Fig 3C). LTA, however, was sensed efficiently via TLR2 (Fig 3D). Furthermore, TLR3 co-transfection resulted in synergistic effects with highly purified *L. monocytogenes* or *S. aureus* LTAs, commercial *B. subtilis* LTA or synthetic lipopeptide (Fig 3D,E). Commercial *S. aureus* LTA did not induce NF-κB activation corroborating previous results (McGrath et al., 2001), whereas *S. pneumoniae* LTA activated mildly (Fig 3D). Interestingly, *S. pneumoniae* LTA has been shown to be less pro-inflammatory in comparison with *S. aureus* LTA (Han et al., 2003), consistent with the fact that the same amount of HK *S. pneumoniae* induced less NF-κB activation via TLR2 (Fig 3B).

PG does not stimulate IL-6 and TNF-α production

Next, we stimulated peritoneal macrophages from C57BL/6J and TLR2-deficient mice with different PG preparations. Whereas cell walls and highly purified LTA (Fig 4A,B) were able to induce tumour necrosis factor-α (TNF-α) in a TLR2-dependent fashion, highly purified PGs were not (Fig 4C). Moreover, highly purified PGs did not induce interleukin-6 (IL-6) production even at 10 µg/ml




Fig 2 | No TLR2-dependent sensing of commercial and soluble peptidoglycan (PG). TLR2-transfected HEK293T cells were stimulated with 'raw' or partially re-purified commercial and highly purified *S. aureus* PG (A). Lysostaphin-digested highly purified *S. aureus* PG was used to stimulate TLR2- (B) or Nod2- (C) transfected HEK293T cells. (D) HPLC profile of the same *S. aureus* digested PG.

(Fig 4D), consistent with the results obtained with transfected HEK293T cells. A lack of cell responses to highly purified PG was observed despite Nod1 and Nod2 expression in these cells (Gutiérrez *et al.* 2002; Chamaillard *et al.* 2003) consistent with the idea that PG must gain entry into the cells for the activation of Nod proteins.

A principal difficulty concerning the identification of which PAMP is detected by a specific TLR resides in the fact that most of these products need to be purified from bacterial cell walls, and therefore contamination with other cell wall components can often occur leading to erroneous conclusions. Indeed, our results suggest that the previous attribution of TLR2 as the receptor of PG is likely to be incorrect as many of these studies relied on impure PG as the stimulus. Our results strongly suggest that cell wall contaminants present in PG preparations are responsible for TLR2-dependent cell activation. For Gram-negative bacterial cell wall preparations, we have shown that TLR2 stimulatory activity is dependent on the presence of covalently bound lipoproteins. TLR2 stimulatory activity of Gram-positive cell walls is likely to be mediated by contaminating LTA.

Interestingly, although Gram-positive cell walls stimulated TLR2 either in transfected HEK293T cells (*L. monocytogenes* and *B. subtilis*) or macrophages (*S. pneumoniae*; *L. monocytogenes* and *B. subtilis*), after hydrofluoric acid treatment this

stimulatory activity was completely lost. Hydrofluoric acid treatment hydrolyses LTA and WTA into their building block subunits (phosphate, D-alanine, choline, sugars, glycerol and/or lipid anchor). A principal argument in favour of LTA instead of WTA as a TLR2 agonist is on the basis of the fact that *S. aureus* and *S. pneumoniae* cell wall preparations, which still have WTA, were not able to induce TLR2 in HEK293T cells. As WTA corresponds grossly to half of the Gram-positive cell wall, the TLR2-stimulating activity present in *S. pneumoniae* cell walls observed with macrophages must be only in trace amounts, excluding WTA as a TLR2 agonist. Accordingly, highly purified LTAs induced a TLR2-dependent NF-κB response. Furthermore, we show for the first time that TLR2 seems to synergize at least with TLR1 to sense LTA. Moreover, chemically synthesized LTA has been reported as a potent inducer of cytokines in monocytes (Morath *et al.* 2002).

Consequently, it is conceivable that the TLR and Nod pathways cooperate to enhance the immunological response. Accordingly, crosstalk between TLR2 and Nod2 has been described recently (Chen *et al.* 2004; Netea *et al.* 2004; Watanabe *et al.* 2004). Cooperation between different sensing pathways is intuitively an advantage for the host, as the response can be more robust, avoiding marked responses to the occasional presence of individual PAMPs. Finally, our observations have the crucial consequence that Nod1 and Nod2 are more than just cytosolic




Fig 3: TLR2-, TLR2/1- and TLR2/6-dependent sensing of heat-killed (HK) bacteria, peptidoglycan (PG) and lipoteichoic acid. The different heat-killed bacterial concentrations were adjusted to obtain equal PG amounts (approximately 1 µg) (A). Dose-dependent HEK293T cells stimulation with tenfold increasing amounts of HK *S. aureus* and *S. pneumoniae* (B), TLR2-, TLR2/1- or TLR2/6-transfected HEK293T cells stimulation with highly purified peptidoglycans (C), *S. pneumoniae* and *L. monocytogenes* LTAs were used to stimulate TLR2 (D). TLR2-, TLR2/1- or TLR2/6-transfected HEK293T cells stimulation with *L. monocytogenes*, *S. aureus* and commercial *B. subtilis* LTAs (E). *L. monocytogenes* LTAs type I and II differ by the addition of a phosphate group to the glycolipid anchor diglucosyldiacylglycerol.

'second fiddle', showing overlapping functions with TLR2 in PG sensing. In fact, the NodS show unique sensing specificities that are not shared by members of the TLR family (Girardin *et al.* 2003c), resolving the controversial findings that NodS and TLR2 seem to recognize the same ligands.

METHODS

Bacterial strains. Bacterial strains used to prepare PG and HK cells were *S. aureus* COL, *L. monocytogenes* EGD, *B. subtilis* 168, *S. pneumoniae* R800, *H. pylori* 26695, *E. coli* MC1061, *Y. pseudotuberculosis* IP32953 and *P. aeruginosa* O1.




Fig 4 | Macrophage sensing of peptidoglycan (PG) and lipoteichoic acid (LTA). Peritoneal macrophages from C57BL/6J and TLR2 $^{-/-}$ mice were stimulated with highly purified *L. monocytogenes* lipoteichoic acid (A,B), PG preparations from each purification step (C) and different concentrations of highly purified *H. pylori*, *S. pneumoniae* and *S. aureus* PGs (D). TNF- α and IL-6 productions were determined by enzyme-linked immunosorbent assay. The purified PG preparations numbered 1–3 correspond to the different purification steps (supplementary Fig 1 online).

Reagents. Pure LPS from *E. coli* F515 was obtained as described (Sanchez Carballo et al., 1999). Pam3CysK4, MDP, commercial *S. aureus* PG and LTA, and *B. subtilis* LTA were from EMC microcollections (Tübingen, Germany), Calbiochem (San Diego, CA, USA), Fluka (Buchs, Switzerland), Sigma-Aldrich (St Louis, MO, USA) and Invivogen (San Diego, CA, USA), respectively. Highly purified *S. aureus* LTA was kindly donated by Thomas Hartung, *L. monocytogenes* ATCC 19115 serotype 4a LTAs type I and II, differing by the addition of a phosphate group to the glycolipid anchor digucosyldiacylglycerol, and *S. pneumoniae* R6 LTA were kindly provided by Pascale Cossart. Endotoxin-free fetal calf serum (FCS) was from Hyclone (Logan, UT, USA). All cell culture reagents and antibiotics were from Life Technology (Cergy, France).

PG purification. PGs from Gram-negative and Gram-positive bacteria were purified as described (Girardin et al., 2003b). PG samples were lyophilized in a speed-vac to estimate the amount of PG and determine the yield per CFU. PG samples were resuspended in pyrogenic-free ultrapure water (Biochrom AG, Berlin, Germany). Amino-acid and amino-sugar composition was determined with a Hitachi L8800 analyser (ScienceTec, Les Ulis, France) after hydrolysis of samples in 6 M HCl at 95 °C for 16 h.

HPLC analysis. *S. aureus* PG was digested with recombinant lysozyme (50 μ g/ml; Sigma) in 50 mM Tris-HCl (pH 8) at 37 °C with stirring for 16 h and was analysed by HPLC as described (Sieradzki et al., 1999), except that buffer A did not contain methanol.

Expression plasmids. NF- κ B reporter (Igk-luciferase) and TLR2 expression plasmids were from Alain Israel (Muñoz et al., 1994) and Marta Muzio (Muzio et al., 1998), respectively. Nod2 expression plasmid was from Gilles Thomas (Fondation Jean Dausset/CEPH, Paris, France). TLR1 and TLR6 expression plasmids (pUro-hTLR1 and pUro-hTLR6) were from Invivogen, and pcDNA3.1 vector was from Invitrogen.

Reporter assays for NF- κ B activation. Human embryonic kidney HEK293T cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FCS. Studies on the synergistic activation of NF- κ B by PGs were carried out as described by Inohara et al. (2002). Briefly, cells were transfected with 75 ng of the reporter plasmid Igk-luc plus the following vectors: 15 ng Nod2, 300 ng TLR2, TLR1 or TLR6. The pcDNA3.1 vector was used to balance the transfected DNA concentration. PG or LTA preparations were used at 1 μ g/ml unless otherwise indicated. Pam3CysK4 (3 μ g/ml) and MDP (1 μ g/ml) were used as positive controls for TLR2

and Nod2, respectively. In the HK experiments, we added for Gram-negative bacteria 10^8 CFU/ml, for *L. monocytogenes* and *B. subtilis* 10^7 CFU/ml, for *S. pneumoniae* $4-5 \times 10^7$ CFU/ml and for *S. aureus* $4-5 \times 10^6$ CFU/ml, respectively to $\sim 5 \times 10^5$ HEK293T cells per millilitre. This represents a multiplicity of infection ranging from 10 to 200 depending on the bacterial species. The data represent mean \pm s.e. of triplicate experiments.

Mice. Female mice (6–10 weeks old) were used for this study. C57BL/6J mice were purchased from Janvier (Le Genest, France). TLR2-deficient mice initially provided by S. Akira (Osaka, Japan) were further backcrossed in C57BL/6J to reach the eighth backcross by Michel Chignard (Institut Pasteur). Mice were submitted to sanitary control tests at the CDTA (Orléans, France) to ensure proper pathogen-free status. All protocols were reviewed by the Institut Pasteur competent authority for compliance with the French and European regulations on Animal Welfare and with Public Health Service recommendations.

Cells. Mouse peritoneal macrophages were elicited by injection of 1.5 ml of thioglycolate medium (Bio-Rad, Hercules, CA, USA) in the peritoneal cavity four days before peritoneal lavage with 5 ml of phosphate-buffered saline (PBS) complemented with Heparin Choay (10 U/ml) from Sanofi (Gentilly, France). Cells from five to six mice were pooled and resuspended to 10^6 cells/ml in RPMI/3% FCS in 24-well plates. After 90 min of incubation (37 °C, 5% CO₂), cells were thoroughly washed with PBS, and 500 µl of RPMI/0.2% FCS/penicillin (100 U/ml)/streptomycin (100 µg/ml)/amphotericin B (250 ng/ml) were added. After 2 h, cells were stimulated in duplicate or triplicate. Unless otherwise indicated in the figure legend, PGs, Pam₃CysSK₄ and MDP were tested at 1 µg/ml and LPS at 100 ng/ml. After 18 h, the supernatants were aliquoted and frozen at -20 °C.

Cytokine dosage. Murine cytokines (TNF-α, IL-6) released into the medium were measured using B-D Pharmingen (San Diego, CA, USA) opt EIA kits. The data represent mean \pm s.e. of triplicate experiments.

Supplementary information is available at *EMBO reports* online (<http://www.emboreports.org/>).

ACKNOWLEDGEMENTS

We thank those who kindly provided us with the different bacterial strains, LTA preparations and TLR2 knockout mice. L.H.T. was supported by a studentship from CAPES/MCT, Brazil. S.E.G. was supported by a grant from Danone Vitapole, Paris, France, and by the Institut Pasteur, Paris, France. I.G.B. was supported by FCT, Portugal, and the Institut Pasteur, Paris, France. I.G.B. is an INSERM Research Associate. This work was supported in part by an Institut Pasteur grant FIR 94.

REFERENCES

- Chamaillard M et al (2003) An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. *Nat Immunol* **4**: 702–707.
- Chen CM, Gong Y, Zhang M, Chen J (2004) Reciprocal cross-talk between Nod2 and TAK1 signaling pathways. *J Biol Chem* **279**: 25876–25882.
- Costa K, Bachet G, Almåier G, Domínguez-Bello MG, Engstrand L, Falk P, de Pedro MA, García del Portillo F (1999) The morphological transition of *Helicobacter pylori* cells from spiral to coccoid is preceded by a substantial modification of the cell wall. *J Bacteriol* **181**: 3710–3718.
- de Jonge BL, Chang YS, Gage D, Tomasz A (1992) Peptidoglycan composition of a highly methicillin-resistant *Staphylococcus aureus* strain. *The role of penicillin-binding protein 2A. J Biol Chem* **267**: 11248–11254.
- Girardin SE et al (2003a) Nod1 detects a unique muropeptide from Gram-negative bacterial peptidoglycan. *Science* **300**: 1584–1587.
- Girardin SE, Boneca IG, Vista J, Chamaillard M, Lahyane A, Thomas G, Philpot DJ, Sansometti PJ (2003b) Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. *J Biol Chem* **278**: 8869–8872.
- Girardin SE, Travassos LH, Herve M, Blanot D, Boneca IG, Philpot DJ, Sansometti PJ, Mengin-Lascoux C (2003c) Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. *J Biol Chem* **278**: 41702–41708.
- Glauner B (1988) Separation and quantification of muropeptides with high-performance liquid chromatography. *Anal Biochem* **172**: 451–464.
- Gutiérrez O, Pipasón C, Ichihara N, Fontalba A, Ogura Y, Prosper F, Núñez G, Fernández-Luna JL (2002) Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-κB activation. *J Biol Chem* **277**: 41701–41703.
- Hari SH, Kim BH, Martin M, Michalek SM, Nahm MH (2003) Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating Toll-like receptor 2. *Infect Immun* **71**: 5341–5346.
- Ichihara N, Ogura Y, Núñez G (2002) Nods: a family of cytosolic proteins that regulate the host response to pathogens. *Curr Opin Microbiol* **5**: 76–80.
- Ichihara N et al (2003) Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. *J Biol Chem* **278**: 5509–5512.
- Merath S, Geyer A, Hartung T (2001) Structure-function relationship of cytokine induction by lipoteichoic acid from *Staphylococcus aureus*. *J Exp Med* **193**: 393–397.
- Merath S, Stadelmaier A, Geyer A, Schmidt RR, Hartung T (2002) Synthetic lipoteichoic acid from *Staphylococcus aureus* is a potent stimulus of cytokine release. *J Exp Med* **195**: 1635–1640.
- Munoz E, Courtois G, Veschambre P, Jalinot P, Israel A (1994) Tax induces nuclear translocation of NF-κB through dissociation of cytoplasmic complexes containing p105 or p100 but does not induce degradation of IκB α/MAD3. *J Virol* **68**: 8035–8044.
- Muzio M, Natoli G, Saccani S, Levra M, Mantovani A (1998) The human jnk signaling pathway: divergence of nuclear factor-κB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). *J Exp Med* **187**: 2097–2101.
- Netea MG, Küller B, de Jonge DJ, Franke B, Sprong T, Naber TH, Orenstein JW, Van der Meer JW (2003) NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. *Eur J Immunol* **33**: 2052–2059.
- Quintela JC, Caparros M, de Pedro MA (1995) Variability of peptidoglycan structural parameters in Gram-negative bacteria. *FEMS Microbiol Lett* **125**: 93–100.
- Sanchez-Cortallo PM, Rietschel ET, Koizumi F, Zähringer U (1999) Elucidation of the structure of an alanine-lacking core tetrasaccharide triphosphate from the lipopolysaccharide of *Pseudomonas aeruginosa* mutant H4. *Eur J Biochem* **263**: 509–508.
- Schleifer KH, Kandler O (1972) Peptidoglycan types of bacterial cell walls and their taxonomic implications. *Bacteriol Rev* **36**: 407–477.
- Schwandner R, Dziarski R, Wessely H, Rosse M, Kirschning CJ (1999) Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. *J Biol Chem* **274**: 17406–17409.
- Sieradzki K, Pinho MG, Tomasz A (1999) Inactivated phsp8 in highly glycopeptide-resistant laboratory mutants of *Staphylococcus aureus*. *J Biol Chem* **274**: 18942–18946.
- Takeda K, Akira S (2003) Toll receptors and pathogen resistance. *Cell Microbiol* **5**: 143–153.
- Tomasz A, Waks S (1975) Mechanism of action of penicillin: triggering of the pneumococcal autolytic enzyme by inhibitors of cell wall synthesis. *Proc Natl Acad Sci USA* **72**: 4162–4166.
- van Langeweld P, van Dissel JT, Ravensbergen E, Appelman B, Schrijver IA, Gommeyns PH (1998) Antimonic-induced release of lipoteichoic acid and peptidoglycan from *Staphylococcus aureus*: quantitative measurements and biological reactivities. *Antimicrob Agents Chemother* **42**: 3073–3078.
- Watsonabe T, Kitani A, Murray PI, Simber W (2004) NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. *Nat Immunol* **5**: 800–808.